Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Videos

Brian Biehn, senior director of biosimilar commercialization at Cencora, makes predictions for how big regulatory approvals in 2023 will shape the biosimilar space going forward.

Cencora's Brian Biehn Forecasts Big Changes for the US Biosimilar Space

Cameron Santoro is an associate editor for The Center for Biosimilars

Here are the top 5 biosimilar articles for the week of December 4, 2023. 

The Top 5 Biosimilar Articles for the Week of December 4

Laura is the editorial director of The American Journal of Managed Care

) and all its brands, including The American Journal of Accountable Care

, Evidence-Based Oncology™, and The Center for Biosimilars

, since 2011. She has an MA in business and economic reporting from New York University.

Articles

A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.

Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.

Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Stakeholders Summit: Provider Education on Biosimilars

Pfizer's Citizen Petition on Biosimilar Communications

Combating Misinformation and Misconceptions About Biosimilars

Targeted Education for Biosimilar Stakeholders

US Versus EU Education on Biosimilars

The FDA's Approach to Biosimilar Education

Biosimilarity, Manufacturing Changes, and Comparability

Clinicians' Understanding of Manufacturing Changes

The Extrapolation of Indications

Selecting the Most Sensitive Population for Confirmatory Trials

Immunogenicity and Biosimilars

Misconceptions About Interchangeability

Clinical Studies for Biosimilars

The Future of US Biosimilars

The Role of Biosimilars in the US Healthcare System

Allowing the US Biosimilars Market to Flourish

Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use

Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars

Madelaine Feldman, MD: Practical Considerations for Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars